
Psychosomatics 46:379-384, October 2005
doi: 10.1176/appi.psy.46.5.379
© 2005 Academy of Psychosomatic Medicine
Evaluation of Reboxetine, a Noradrenergic Antidepressant, for the Treatment of Fibromyalgia and Chronic Low Back Pain
Heather V. Krell, M.D., M.P.H.,
Andrew F. Leuchter, M.D.,
Ian A. Cook, M.D., and
Michelle Abrams, R.N.
Received Dec. 4, 2003; revision received Oct. 27, 2004; accepted Nov. 15, 2004. From the Laboratory of Behavioral Pharmacology, UCLA Neuropsychiatric Institute. Address correspondence and reprint requests to Dr. Krell, UCLA Neuropsychiatric Institute, 37-452 NPI, 760 Westwood Plaza, Los Angeles, CA 90024; hkrell{at}mednet.ucla.edu (e-mail).
Clinical experience supports the use of antidepressant medications to treat chronic pain syndromes, such as low back pain and fibromyalgia. Although this use of antidepressants is common in clinical practice, the literature supporting this off-label use has some limitations. In this report, the authors review the body of clinical data on the use of antidepressants in treating pain and present a case series of depressed patients with these syndromes who experienced relief of pain symptoms while being treated with the noradrenergic antidepressant reboxetine. These subjects experienced significant relief of pain before any significant improvement in actual mood symptoms. Our experience with reboxetine suggests that this noradrenergic antidepressant may have efficacy in the treatment of chronic pain in patients with depression.
This article has been cited by other articles:

|
 |

|
 |
 
V. HAINER, K. KABRNOVA, B. ALDHOON, M. KUNESOVA, and M. WAGENKNECHT
Serotonin and Norepinephrine Reuptake Inhibition and Eating Behavior
Ann. N.Y. Acad. Sci.,
November 1, 2006;
1083(1):
252 - 269.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Get information about faster international access.
a>
Privacy Policy
Copyright © 2005
Academy of Psychosomatic Medicine.
All rights reserved.
Home
| Search
| Current Issue
| Past Issues
| Subscribe
| All APPI Journals
| Help
| Contact Us
|